瑞舒伐他汀钙片联合盐酸吡格列酮片对Ⅱ型糖尿病患者血脂及颈动脉粥样硬化的影响

目的观察瑞舒伐他汀钙片联合盐酸吡格列酮片对Ⅱ型糖尿病患者血脂及颈动脉粥样硬化的影响.方法96例Ⅱ型糖尿病患者随机分成对照组与治疗组,对照组单独服用瑞舒伐他汀钙片,治疗组同时服用瑞舒伐他汀钙片与盐酸吡格列酮片.治疗20个月后观察患者空腹血糖(FPG)、甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、颈动脉内中膜厚度(IMT)及颈动脉斑块Crouse积分等变化.结果治疗前后各组组内比较,对照组TC及LDL明显下降,具有统计学意义(P0.01);IMT、颈动脉斑块Crouse积分下降,具有统计学意义(P0.05);HDL呈升高趋势,但无统计学意义(P0.05).治疗组TC,LDL,TG及FPG明显下降,具有统计学意义(P0.01);IMT、颈动脉斑块Crouse积分均下降,具有统计学意义(P0.05);HDL升高,具有统计学意义(P0.05).治疗后各组组间比较HDL明显升高,具有统计学意义(P0.01);FPG,TG,IMT,颈动脉斑块Crouse积分下降,具有统计学意义(P0.05).结论与单独应用瑞舒伐他汀钙片比较,联合应用瑞舒伐他汀钙片与盐酸吡格列酮片能进一步降低TG,IMT及颈动脉斑块Crouse积分,显著升高HDL.

Effects of Pioglitazone and Rosuvastatin Combination Therapy on Serum Lipid and Carotid Atherosclerosis in Type 2 Diabetes

Objective To investigate the effects of pioglitazone and rosuvastatin combination therapy on serum lipid and carotid atherosclerosis in type 2 diabetes, and to explore the relationship between serum lipid and atherosclerosis. Method Ninety-six cases of type 2 diabetes patients were randomly divided into two groups:control group and treatment group. The control group was given rosuvastatin,and the treatment group was given rosuvastatin and pioglitazone. At the baseline and the end of the treatment, carotid intimal-medial ( IMT ) thickness and integral for carotid plaque Crouse were detected by ultrasound,simultaneously,the levels of fasting plasma glucose (FPG),triglycerides(TG),total cholesterol (TC),low density lipoprotein (LDL) and high density lipoprotein ( HDL) were also determined. Results Comparison within each group before and after treatment,in the rosuvastatin group,both TC and LDL decreased obviously with significant differences (P<0. 01),the carotid intima-media thickness and carotid plaque Crouse score decreased with statistical differences (P<0. 05),HDL showed ascendant trend without significance. In the therapy group, all the levels of TC, LDL, TG and FPG decreased obviously with significant differences(P<0. 01),the carotid intima-media thickness and carotid plaque Crouse score decreased with statistical differences (P<0. 05),and HDL rised with statistical differences (P<0. 05). Compared with the control group,the level of HDL increased obviously with statistical differences (P<0. 01) in the treatment group. The levels of FPG and TG, carotid intima-media thickness and carotid plaque Crouse score decreased significantly (P<0. 05). Conclusion Compared with rosuvastatin alone,rosuvastatin and pioglitazone combination therapy in patients with type 2 diabetes can significantly increase HDL level,further lower TG and decrease carotid intima-media thickness and carotid plaque Crouse score.